A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...

Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while ...

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion ...

The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face ...

Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics ...

A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford ...